Pharmaceuticals
KSMs, APIs, CDMOs, US generics, branded India and biologics - India's medicine value chain
What this is
- India branded medicines: ~₹2.4L Cr, growing high single to low double digits; price control is the cap.
- US and export generics: large but deflationary; returns need complex products and a clean USFDA record.
- Specialty, biosimilars and vaccines: the highest value and the highest risk.
- Chemistry and outsourcing (APIs, CDMOs): re-rated by China+1 and GLP-1 demand, but still cyclical.
Why now
- US generics profits are past their peak, as the one-off gains from generic Revlimid fade.
- US tariffs on generics are 0% until Aug 2028, then 100%, then 200% for companies without US plants.
- India's branded market grows ~10% a year; semaglutide went generic here in March 2026.
- The BIOSECURE Act (Dec 2025) is moving Western biotech work away from Chinese CDMOs.
- Sun Pharma's US$11.75bn Organon deal shows leaders buying into innovative medicines.
What to watch
- Monthly IPM value and unit growth (Pharmarack / IQVIA)
- USFDA inspection outcomes: Form 483s, OAIs, warning letters, import alerts
- US generic price erosion and big-product exclusivity cliffs (gRevlimid, gMyrbetriq, gSpiriva)
- US Section 232 / generic-tariff timeline and India-US trade deal terms
- CDMO order books, RFP inflow and validation-batch commentary (BIOSECURE shift)
- China KSM/API import prices and PLI bulk-drug commissioning
Major areas
The map groups the anatomy into these areas before you drop into individual components.
India market
Branded formulations sold to Indian doctors and patients, and the distributors, chains and e-pharmacies that move them - a price-controlled but steadily growing, brand-driven market.
Specialty & innovation
Patented and specialty medicines, novel molecules and out-licensing deals - the highest-margin, highest-risk layer that Indian leaders are now building into.
Global generics
Off-patent oral solids, complex generics and sterile injectables sold mainly into the US, Europe and emerging markets - large, deflationary and regulator-gated.
Biologics & vaccines
Biosimilars, insulins and vaccines made in living cells - capital-heavy, slow to approve, but with fewer competitors and longer product lives than small-molecule generics.
Chemistry & inputs
Key starting materials, intermediates, APIs and the excipients and primary packaging every finished dose needs - where India's China dependence and PLI build-out sit.
CDMO & research outsourcing
Contract research, development and manufacturing for global innovators - India's China+1 and BIOSECURE opportunity.
Branded drugmakers
The companies whose names are on the medicine: they own the brands, field forces and doctor relationships, and sell finished formulations to India's 12 lakh-plus pharmacies - the steadiest, highest-return profit pool in Indian pharma.
Sun Pharmaceutical Industries
ListedIndia's largest drugmaker: No. 1 in the Indian branded market, a growing global innovative-medicines (specialty) business and US generics via Sun and Taro
Mankind Pharma
ListedIndia-focused branded generics leader - No. 1 by prescription volume, strong in tier-2/3 towns, plus OTC brands and (since 2024) Bharat Serums & Vaccines
Torrent Pharmaceuticals
ListedChronic-focused branded formulations (cardiac, CNS, GI, diabetes) in India, Brazil and Germany; absorbed J B Chemicals in 2026
Alkem Laboratories
ListedTop-5 Indian branded formulations company, strongest in anti-infectives and GI (Clavam, Pan), with a US generics arm and Enzene biologics/CDMO subsidiary
Abbott India
ListedIndian listed arm of Abbott Laboratories selling branded formulations (Thyronorm, Duphaston, Udiliv, Digene) - a pure domestic play
Eris Lifesciences
ListedChronic-focused Indian branded formulations (diabetes, cardiac, derma) built through acquisitions, now including insulins and injectables
Cipla
ListedNo. 3 Indian branded formulations company and respiratory specialist, with a US complex-generics (inhalers, peptides) business and South Africa
Zydus Lifesciences
ListedDiversified major: US generics (~45% of sales), India branded formulations, consumer wellness, vaccines/biosimilars and an in-house NCE pipeline
Ipca Laboratories
ListedVertically integrated maker of branded formulations (pain - Zerodol, anti-malarials, cardiac) and APIs, with Unichem adding US/Europe generics
Ajanta Pharma
ListedBranded generics in India (cardiac, ophthalmology, derma), Asia and Africa, plus a US generics business
Intas Pharmaceuticals
UnlistedUnlisted top-3 Indian drugmaker - India branded formulations plus Accord (Europe/US generics) and Accord BioPharma biosimilars
Potential bottlenecks
- Price control: ~15-18% of the market sits under NLEM/DPCO ceiling prices, and NPPA can cap trade margins or add drugs to the listIndia branded formulations
- Field-force productivity - MR costs rise every year and incremental reps add lessIndia branded formulations
- Trade-generic and Jan Aushadhi channels pressure prices in commoditised moleculesIndia branded formulations
- Revised Schedule M (WHO-GMP aligned) raises compliance cost for smaller makersIndia branded formulations
- Small R&D budgets versus global innovators (Indian leaders spend ~US$100-400m a year)Specialty & innovation (R&D)
- Few Indian companies have US/EU specialty sales infrastructureSpecialty & innovation (R&D)
- Slow Indian clinical-trial approvals (CDSCO) push trials abroadSpecialty & innovation (R&D)
- Regulated trade margins limit pricingDistribution & pharmacy retail
- Working-capital intensity (inventory and stockist credit)Distribution & pharmacy retail
- Unregulated e-pharmacy rules and pushback from chemist associations (AIOCD)Distribution & pharmacy retail
- USFDA facility status gates approvals: an OAI or warning letter freezes new launches from that plantGenerics (US & export)
- Consolidated US buyers (three purchasing groups buy most generics) hold pricing powerGenerics (US & export)
- Complex generics need device, clinical-endpoint and bioequivalence capabilities few companies haveGenerics (US & export)
- Type-I borosilicate glass tubing comes from a handful of global suppliersPackaging, glass & excipients
- Process-safety risk in powder handling (the June 2025 Sigachi Pashamylaram explosion)Packaging, glass & excipients
- Qualification with each customer takes 12-24 monthsPackaging, glass & excipients
- Aseptic compliance - sterility assurance and data integrity are frequent 483 findingsSterile injectables & fill-finish
- Long build and validation times for new sterile linesSterile injectables & fill-finish
- Glass and component supply (vials, stoppers, cartridges)Sterile injectables & fill-finish
- Development cost and time (7-8 years per biosimilar)Biosimilars, vaccines & biologics
- US interchangeability and payer access (PBM formularies)Biosimilars, vaccines & biologics
- Cold-chain and fill-finish capacityBiosimilars, vaccines & biologics
- Dependence on Chinese KSMs and intermediates (70%+ of imports for many critical APIs come from China, per PIB data cited for FY24-FY25)APIs (active ingredients)
- Environmental clearances and effluent treatment for chemistry sitesAPIs (active ingredients)
- Solvent and energy cost volatilityAPIs (active ingredients)
- Chinese scale and cost advantage (cheaper energy, integrated chemical parks)KSMs & intermediates
- Fermentation capacity for antibiotics (penicillin G) is capital-heavyKSMs & intermediates
- Environmental approvals for new chemistry sitesKSMs & intermediates
- Scientific talent and senior process-chemistry depthCDMO & contract research
- Customer qualification and audit cycles of 1-3 yearsCDMO & contract research
- Capacity in peptides, oligonucleotides, ADCs and biologicsCDMO & contract research
Companies in this theme
54 companies, 46 listed. The 11 branded drugmakers are listed above.
Glenmark Pharmaceuticals
ListedBranded formulations (India derma/respiratory, Europe, emerging markets), US generics and the Ichnos Glenmark Innovation (IGI) biotech arm
Company page →Lupin
ListedUS complex generics (inhalation, injectables), India branded formulations and specialty assets
Company page →Wockhardt
ListedAntibiotic discovery company - first Indian-discovered NCE antibiotic approved by the US FDA (Zaynich, 2026) - plus generics in India, UK and emerging markets
Company page →SPARC (Sun Pharma Advanced Research Company)
ListedSun Pharma group's pure R&D company developing novel drugs and delivery platforms for out-licensing
Company page →MedPlus Health Services
ListedIndia's second-largest pharmacy retail chain, with a large private-label generics push
Company page →Apollo Hospitals Enterprise
ListedHospital group whose Apollo HealthCo arm runs India's largest pharmacy chain (7,000+ stores), Apollo 24/7 and, via Keimed, wholesale pharma distribution
Company page →Entero Healthcare Solutions
ListedPan-India pharma and healthcare-product distributor consolidating fragmented regional wholesalers
Company page →PharmEasy (API Holdings)
UnlistedUnlisted e-pharmacy and B2B distribution platform (PharmEasy, Retailio, Thyrocare parent)
Tata 1mg
UnlistedUnlisted e-pharmacy, diagnostics and teleconsultation platform owned by Tata Digital
Dr Reddy's Laboratories
ListedUS generics major (largest single market), India branded formulations, emerging markets, APIs (PSAI) and biosimilars
Aurobindo Pharma
ListedLargest Indian exporter of generics to the US by volume, with Eugia injectables, Europe, APIs and a Pen-G KSM project
Alembic Pharmaceuticals
ListedUS generics (oral solids, injectables, oncology, derma) with India branded formulations and APIs
Natco Pharma
ListedNiche US generics through Para IV challenges and partners (gRevlimid with Teva), India oncology, agrochemicals and an Africa platform
Company page →Granules India
ListedVertically integrated maker of high-volume molecules (paracetamol, metformin, ibuprofen) from KSM to API to formulations, mainly for the US
Senores Pharmaceuticals
ListedYoung US-focused generics company with an Atlanta (US) manufacturing site plus emerging-market and critical-care injectables
Company page →Sigachi Industries
ListedOne of the world's largest makers of microcrystalline cellulose (MCC), a key tablet excipient
Company page →Borosil Scientific
ListedLaboratory glassware and instruments plus pharma primary packaging (Klasspack vials, ampoules and cartridges)
Company page →SCHOTT Poonawalla
UnlistedUnlisted maker of Type-I borosilicate glass vials, ampoules, cartridges and prefilled syringes for injectables
ACG Worldwide
UnlistedUnlisted maker of empty hard capsules, barrier films/foils and pharma processing and packaging machinery
Gland Pharma
ListedB2B sterile injectables developer and contract manufacturer (vials, bags, prefilled syringes) for global generic and innovator companies; owns Cenexi in Europe
Company page →Caplin Point Laboratories
ListedBranded generics in Latin America plus Caplin Steriles, a growing US injectables and ophthalmics business
Company page →Piramal Pharma
ListedGlobal CDMO (Piramal Pharma Solutions), complex hospital generics (inhaled anaesthetics, intrathecal therapies) and India consumer health
Biocon
ListedIndia's largest biosimilars company (Biocon Biologics, now 100% owned) plus generics/APIs and a majority stake in Syngene
Company page →Serum Institute of India
UnlistedUnlisted - world's largest vaccine maker by doses (measles, DTP, pneumococcal, HPV, malaria R21)
Bharat Biotech
UnlistedUnlisted vaccine developer (Covaxin, Rotavac, typhoid conjugate, nasal COVID vaccine)
Biological E
UnlistedUnlisted vaccine and biologics maker (Corbevax, PCV14, pentavalent, typhoid)
Panacea Biotec
ListedListed vaccine maker - WHO-prequalified pentavalent (Easyfive-TT) for UNICEF/Gavi, and a dengue vaccine (DengiAll) in Phase 3 with ICMR
Company page →Divi's Laboratories
ListedGlobal leader in generic APIs (naproxen, gabapentin, dextromethorphan and others) and custom synthesis for big pharma, including peptides and GLP-1 building blocks
Company page →Laurus Labs
ListedAPI maker (ARVs, oncology, CVS) turning into a CDMO (Laurus Synthesis) with formulations and Laurus Bio
Company page →Aarti Drugs
ListedHigh-volume API maker (metformin, ciprofloxacin, antifungals) backward-integrated into its own intermediates
Company page →Solara Active Pharma Sciences
ListedAPI maker (ibuprofen among the world's largest, plus anti-infectives and CNS) spun out of the Strides group
Company page →Concord Biotech
ListedFermentation-based APIs - a global leader in immunosuppressants (mycophenolate, tacrolimus) and anti-infectives - moving into formulations
Company page →Neuland Laboratories
ListedComplex and peptide APIs plus custom manufacturing (CMS) for innovator molecules
Company page →IOL Chemicals & Pharmaceuticals
ListedOne of the world's largest ibuprofen makers, integrated back into KSMs and basic chemicals (isobutylbenzene, ethyl acetate)
Company page →Vinati Organics
ListedSpecialty chemicals maker and global leader in isobutylbenzene (IBB), the key starting material for ibuprofen
Company page →Aarti Pharmalabs
ListedPharma intermediates, xanthine derivatives (caffeine) and APIs, with a CDMO business
Company page →Syngene International
ListedIndia's largest CRO/CDMO - discovery, development and manufacturing for global pharma and biotech, including biologics
Company page →Sai Life Sciences
ListedSmall-molecule CRDMO serving innovator pharma and biotech from discovery to commercial supply
Company page →Anthem Biosciences
ListedBengaluru CRDMO covering small molecules, peptides, oligos and fermentation-based specialty ingredients
Company page →Cohance Lifesciences
ListedCDMO formed from Suven Pharmaceuticals and Cohance (Advent-backed), with NJ Bio adding antibody-drug-conjugate (ADC) services
Company page →Dishman Carbogen Amcis
ListedCDMO for high-potency APIs and late-stage/commercial molecules via Swiss subsidiary Carbogen Amcis
Company page →Akums Drugs & Pharmaceuticals
ListedIndia's largest contract manufacturer of formulations for domestic pharma brands, plus trade generics and APIs
Company page →Common questions
Which listed companies are in India's Pharmaceuticals supply chain?
NextResearch maps 46 listed companies across 10 layers of the Pharmaceuticals supply chain. The largest with high exposure, by market cap as of 30 Oct 2026: Sun Pharmaceutical Industries (₹4.26L Cr), Divi's Laboratories (₹2.60L Cr), Torrent Pharmaceuticals (₹1.76L Cr), Laurus Labs (₹1.30L Cr) and Zydus Lifesciences (₹1.24L Cr).
What are the layers of the Pharmaceuticals supply chain?
10 layers: India branded formulations; Specialty & innovation (R&D); Distribution & pharmacy retail; Generics (US & export); Packaging, glass & excipients; Sterile injectables & fill-finish; Biosimilars, vaccines & biologics; APIs (active ingredients); KSMs & intermediates; and CDMO & contract research.
Who are the end players in Pharmaceuticals?
In the India branded formulations layer: Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Zydus Lifesciences, Cipla, Mankind Pharma, Alkem Laboratories, Abbott India, Ipca Laboratories and 3 more.
What are the bottlenecks in India's Pharmaceuticals supply chain?
India branded formulations: Price control: ~15-18% of the market sits under NLEM/DPCO ceiling prices, and NPPA can cap trade margins or add drugs to the list. Specialty & innovation (R&D): Small R&D budgets versus global innovators (Indian leaders spend ~US$100-400m a year). Distribution & pharmacy retail: Regulated trade margins limit pricing. Generics (US & export): USFDA facility status gates approvals: an OAI or warning letter freezes new launches from that plant. More by layer on this page.